Radium-223 in mCPRC patients: a large real-life Italian multicenter study-Reference-Cited by-同舟云学术

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

Published:2022-03 Issue:1 Volume:74 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

FRANTELLIZZI Viviana,MONARI Fabio,MASCIA Manlio,COSTA Renato P.,RUBINI Giuseppe,SPANU Angela,FARCOMENI Alessio,LODI RIZZINI Elisa,CINDOLO Luca,TRIPOLI Vincenzo,LAVELLI Valentina,NUVOLI Susanna,PONTICO Mariano,DIONISI Valeria,FERRARI Cristina,DE VINCENTIS Giuseppe

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2022N01A0021

Reference30 articles.

1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

2. Narrative medicine in metastatic prostate cancer reveals ways to improve patient awareness & quality of care

3. Management of metastatic castration-resistant prostate cancer: A focus on radium-223

4. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives;Cancers;2023-09-27

2. The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study;Biomedicines;2023-04-05

3. The current evidence on prognostic factors in metastatic castration-resistant prostate cancer patients treated with Radium-223;Minerva Urology and Nephrology;2023-01